Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with ...
Melissa Pereira Machado +8 more
doaj +1 more source
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]
Farmacia Hospitalaria, 2015 Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz +2 more
doaj +1 more source
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors [PDF]
, 2014 Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL which activates a number of signal transduction pathways, including PI3K/AKT signaling and consequently inactivates FOXO transcription factors.
Bhatia +38 more
core +2 more sources
Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]
PLoS ONE, 2012 BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle +6 more
doaj +1 more source
BCR-ABL Tyrosine Kinase Domain Mutations Combinations Affects Imat inib Resistence in Chronic Phase Chronic Myelogenous Leukemia [PDF]
, 2019 Background: Chronic myelogenous leukemia is a myeloproliferative disease, due to reciprocal translocations of chromosome 9 and 22, resulting to Bcr-Abl fusion gene.
Amrita P N A +4 more
core
Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]
, 2010 Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Alison M. Michie +47 more
core +1 more source
Novel clinical trial designs emerging from the molecular reclassification of cancer
CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam +4 more
wiley +1 more source
Biomolecular Concepts, 2021 The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome +3 more
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]
, 1991 Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard) +2 more
core +1 more source